Outcome parameters for trials in atrial fibrillation

Executive summary - Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)

Paulus Kirchhof, Angelo Auricchio, Jeroen Bax, Harry Crijns, John Camm, Hans Christoph Diener, Andreas Goette, Gerd Hindricks, Stefan Hohnloser, Lukas Kappenberger, Karl Heinz Kuck, Gregory Y H Lip, Bertil Olsson, Thomas Meinertz, Silvia Priori, Ursula Ravens, Gerhard Steinbeck, Elisabeth Svernhage, Jan Tijssen, Alphons Vincent & 1 others Günter Breithardt

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.

Original languageEnglish
Pages (from-to)2803-2817
Number of pages15
JournalEuropean Heart Journal
Volume28
Issue number22
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Mental Competency
Atrial Fibrillation
Consensus
Stroke
Morbidity
Therapeutics
Mortality
Bradycardia
Left Ventricular Function
Tachycardia
Cardiac Arrhythmias
Heart Failure
Quality of Life
Outcome Assessment (Health Care)
Clinical Trials
Costs and Cost Analysis

Keywords

  • Antiarrhythmic drugs
  • Atrial fibrillation
  • Cardioversion
  • Catheter ablation
  • Controlled trial
  • End-point
  • Left ventricular function
  • Outcome parameter
  • Quality of life
  • Randomized trial
  • Rate control
  • Rhythm control
  • Stroke death
  • Therapy, treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Outcome parameters for trials in atrial fibrillation : Executive summary - Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). / Kirchhof, Paulus; Auricchio, Angelo; Bax, Jeroen; Crijns, Harry; Camm, John; Diener, Hans Christoph; Goette, Andreas; Hindricks, Gerd; Hohnloser, Stefan; Kappenberger, Lukas; Kuck, Karl Heinz; Lip, Gregory Y H; Olsson, Bertil; Meinertz, Thomas; Priori, Silvia; Ravens, Ursula; Steinbeck, Gerhard; Svernhage, Elisabeth; Tijssen, Jan; Vincent, Alphons; Breithardt, Günter.

In: European Heart Journal, Vol. 28, No. 22, 11.2007, p. 2803-2817.

Research output: Contribution to journalArticle

Kirchhof, P, Auricchio, A, Bax, J, Crijns, H, Camm, J, Diener, HC, Goette, A, Hindricks, G, Hohnloser, S, Kappenberger, L, Kuck, KH, Lip, GYH, Olsson, B, Meinertz, T, Priori, S, Ravens, U, Steinbeck, G, Svernhage, E, Tijssen, J, Vincent, A & Breithardt, G 2007, 'Outcome parameters for trials in atrial fibrillation: Executive summary - Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)', European Heart Journal, vol. 28, no. 22, pp. 2803-2817. https://doi.org/10.1093/eurheartj/ehm358
Kirchhof, Paulus ; Auricchio, Angelo ; Bax, Jeroen ; Crijns, Harry ; Camm, John ; Diener, Hans Christoph ; Goette, Andreas ; Hindricks, Gerd ; Hohnloser, Stefan ; Kappenberger, Lukas ; Kuck, Karl Heinz ; Lip, Gregory Y H ; Olsson, Bertil ; Meinertz, Thomas ; Priori, Silvia ; Ravens, Ursula ; Steinbeck, Gerhard ; Svernhage, Elisabeth ; Tijssen, Jan ; Vincent, Alphons ; Breithardt, Günter. / Outcome parameters for trials in atrial fibrillation : Executive summary - Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). In: European Heart Journal. 2007 ; Vol. 28, No. 22. pp. 2803-2817.
@article{ae780bb6052f41619b12fb9e8962120f,
title = "Outcome parameters for trials in atrial fibrillation: Executive summary - Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)",
abstract = "Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.",
keywords = "Antiarrhythmic drugs, Atrial fibrillation, Cardioversion, Catheter ablation, Controlled trial, End-point, Left ventricular function, Outcome parameter, Quality of life, Randomized trial, Rate control, Rhythm control, Stroke death, Therapy, treatment",
author = "Paulus Kirchhof and Angelo Auricchio and Jeroen Bax and Harry Crijns and John Camm and Diener, {Hans Christoph} and Andreas Goette and Gerd Hindricks and Stefan Hohnloser and Lukas Kappenberger and Kuck, {Karl Heinz} and Lip, {Gregory Y H} and Bertil Olsson and Thomas Meinertz and Silvia Priori and Ursula Ravens and Gerhard Steinbeck and Elisabeth Svernhage and Jan Tijssen and Alphons Vincent and G{\"u}nter Breithardt",
year = "2007",
month = "11",
doi = "10.1093/eurheartj/ehm358",
language = "English",
volume = "28",
pages = "2803--2817",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "22",

}

TY - JOUR

T1 - Outcome parameters for trials in atrial fibrillation

T2 - Executive summary - Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)

AU - Kirchhof, Paulus

AU - Auricchio, Angelo

AU - Bax, Jeroen

AU - Crijns, Harry

AU - Camm, John

AU - Diener, Hans Christoph

AU - Goette, Andreas

AU - Hindricks, Gerd

AU - Hohnloser, Stefan

AU - Kappenberger, Lukas

AU - Kuck, Karl Heinz

AU - Lip, Gregory Y H

AU - Olsson, Bertil

AU - Meinertz, Thomas

AU - Priori, Silvia

AU - Ravens, Ursula

AU - Steinbeck, Gerhard

AU - Svernhage, Elisabeth

AU - Tijssen, Jan

AU - Vincent, Alphons

AU - Breithardt, Günter

PY - 2007/11

Y1 - 2007/11

N2 - Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.

AB - Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Cardioversion

KW - Catheter ablation

KW - Controlled trial

KW - End-point

KW - Left ventricular function

KW - Outcome parameter

KW - Quality of life

KW - Randomized trial

KW - Rate control

KW - Rhythm control

KW - Stroke death

KW - Therapy, treatment

UR - http://www.scopus.com/inward/record.url?scp=36248929793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248929793&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehm358

DO - 10.1093/eurheartj/ehm358

M3 - Article

VL - 28

SP - 2803

EP - 2817

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 22

ER -